Antiplatelet therapies for the treatment of cardiovascular disease
- 1 February 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (2) , 154-169
Abstract
Antiplatelet therapy has been successful in reducing mortality and morbidity in acute myocardial infarction. Recent advances in understanding the molecular basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity. This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.Keywords
This publication has 152 references indexed in Scilit:
- Interaction Between Cigarette Smoking and Clinical Benefit of ClopidogrelJACC, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Small-molecule inhibitors of integrin α 2 β 1 that prevent pathological thrombus formation via an allosteric mechanismProceedings of the National Academy of Sciences, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide studyBritish Journal of Clinical Pharmacology, 2008
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008
- A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor γ-chain complexJournal of Clinical Investigation, 2008
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002